FDA Clearance Tracker · P240011-S004
Medtronic Altaviva System
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 19, 2025
Approved
Time to decision
28 days
Received Nov 21, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240011-S004
- Device name
- Medtronic Altaviva System
- Applicant
- Medtronic Neuromodulation
- Applicant location
- Minneapolis, MN
- Received
- Nov 21, 2025
- Decided
- Dec 19, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240011
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
The protocol modifications include the addition of quality-of-life, work productivity, mental health, and sexual health questionnaires. Additional revisions included changing "up to 30 institutions" to "approximately 30 institutions", requirements for appropriate investigator training, education, and experience, and updated language regarding the 6-month washout period for botulinum toxin therapy and sacral neuromodulation.
Source documents
Other decisions for Medtronic Neuromodulation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P240011 · Decided Sep 18, 2025 · 532 days after receipt
Device type: Stimulator, tibial, electrical, implantable, for urinary incontinence (QPT) · GI, Urology & Nephrology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.